Efficacy and safety of abatacept compared with etanercept in patients with rheumatoid arthritis in the real world using propensity score matching method
Objective: There are increasing opportunities to use biological disease-modifying antirheumatic drugs and Janus kinase inhibitors, even in elderly patients with rheumatoid arthritis（RA）. We evaluated the use of abatacept（ABT）, which is often used in elderly patients with RA. A comparative study was...
Saved in:
| Published in | Clinical Rheumatology and Related Research Vol. 36; no. 2; pp. 114 - 130 |
|---|---|
| Main Authors | , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | Japanese |
| Published |
The Japanese Society for Clinical Rheumatology and Related Research
2024
一般社団法人 日本臨床リウマチ学会 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0914-8760 2189-0595 |
| DOI | 10.14961/cra.36.114 |
Cover
| Abstract | Objective: There are increasing opportunities to use biological disease-modifying antirheumatic drugs and Janus kinase inhibitors, even in elderly patients with rheumatoid arthritis（RA）. We evaluated the use of abatacept（ABT）, which is often used in elderly patients with RA. A comparative study was conducted with etanercept（ETN）, also for RA.Methods: The clinical course data for 143 of 241 patients with RA treated with ABT at Niigata Rheumatic Center and Asahikawa Medical University from July 2010 to March 2018 and those aged 65 years or older were analyzed at 24 months. In addition, the clinical course data of 170 out of 463 patients with RA treated with ETN at the same hospital between May 2008 and March 2018 who were 65 years or older were analyzed and compared using the propensity score matching（PSM）method.Results: The average age of 143 patients treated with ABT was 75.4 ± 6.2 years and disease activity scores improved significantly; the continuation rate at 24 months was 80.4%. The ABT group had significantly lower disease activity, more PSL reduction, and higher continuation rate compared with the ETN group using the PSM method.Conclusion: ABT is an effective treatment for elderly patients with RA over 65 years old and is significantly better at improving disease activity than ETN. |
|---|---|
| AbstractList | Objective: There are increasing opportunities to use biological disease-modifying antirheumatic drugs and Janus kinase inhibitors, even in elderly patients with rheumatoid arthritis（RA）. We evaluated the use of abatacept（ABT）, which is often used in elderly patients with RA. A comparative study was conducted with etanercept（ETN）, also for RA.Methods: The clinical course data for 143 of 241 patients with RA treated with ABT at Niigata Rheumatic Center and Asahikawa Medical University from July 2010 to March 2018 and those aged 65 years or older were analyzed at 24 months. In addition, the clinical course data of 170 out of 463 patients with RA treated with ETN at the same hospital between May 2008 and March 2018 who were 65 years or older were analyzed and compared using the propensity score matching（PSM）method.Results: The average age of 143 patients treated with ABT was 75.4 ± 6.2 years and disease activity scores improved significantly; the continuation rate at 24 months was 80.4%. The ABT group had significantly lower disease activity, more PSL reduction, and higher continuation rate compared with the ETN group using the PSM method.Conclusion: ABT is an effective treatment for elderly patients with RA over 65 years old and is significantly better at improving disease activity than ETN. Objective: There are increasing opportunities to use biological disease-modifying antirheumatic drugs and Janus kinase inhibitors, even in elderly patients with rheumatoid arthritis（RA）. We evaluated the use of abatacept（ABT）, which is often used in elderly patients with RA. A comparative study was conducted with etanercept（ETN）, also for RA.Methods: The clinical course data for 143 of 241 patients with RA treated with ABT at Niigata Rheumatic Center and Asahikawa Medical University from July 2010 to March 2018 and those aged 65 years or older were analyzed at 24 months. In addition, the clinical course data of 170 out of 463 patients with RA treated with ETN at the same hospital between May 2008 and March 2018 who were 65 years or older were analyzed and compared using the propensity score matching（PSM）method.Results: The average age of 143 patients treated with ABT was 75.4 ± 6.2 years and disease activity scores improved significantly; the continuation rate at 24 months was 80.4%. The ABT group had significantly lower disease activity, more PSL reduction, and higher continuation rate compared with the ETN group using the PSM method.Conclusion: ABT is an effective treatment for elderly patients with RA over 65 years old and is significantly better at improving disease activity than ETN. 目的：関節リウマチ（RA）患者の高齢化に伴い，高齢RA患者に対しても生物学的製剤やヤヌスキナーゼ（JAK）阻害薬を使用する機会が増えている．その作用機序や全例調査結果などから高齢RA患者に使用される機会の多いアバタセプト（ABT）の使用状況について解析し，また血中半減期の短さなどから同じく高齢RA患者に使用されてきたエタネルセプト（ETN）と比較検討する．対象･方法：2010年7月から2018年3月に新潟県立リウマチセンターおよび旭川医科大学病院でABTを導入した241例のRA患者のうち，導入時の年齢が65歳以上であった143例を対象に，24か月を最終評価時として有効性や安全性をretrospectiveに解析した．また2008年5月から2018年3月に同院でETNを導入した463例のRA患者のうち，導入時の年齢が65歳以上の170例と，プロペンシティスコアマッチング（PSM）法を用いて解析し比較した．結果：65歳以上でABTを導入した患者の平均年齢は75.4±6.2歳で，疾患活動性スコアはいずれも有意に改善を認め，継続率は80.4%であった．PSM法を用いて解析したETN群との比較では，ABT群で疾患活動性，PSL減少量，継続率が有意に優れていた．結論：65歳以上の高齢RA患者においてABTは有効な治療手段であり，ETNと比べ疾患活動性の改善が有意に優れていた． |
| Author | Kodama, Satoru Kurosawa, Yoichi Makino, Yuichi Murasawa, Akira Hasegawa, Eriko Kobayashi, Daisuke Takai, Chinatsu Sakai, Shunsuke Nakazono, Kiyoshi Ishikawa, Hajime Abe, Asami Sato, Hiroe Ito, Satoshi Otani, Hiroshi |
| Author_FL | Hasegawa Eriko Kodama Satoru 牧野 雄一 村澤 章 髙井 千夏 坂井 俊介 黒澤 陽一 小林 大介 石川 肇 佐藤 弘恵 阿部 麻美 中園 清 伊藤 聡 大谷 博 |
| Author_FL_xml | – sequence: 1 fullname: Kodama Satoru – sequence: 2 fullname: 伊藤 聡 – sequence: 3 fullname: 阿部 麻美 – sequence: 4 fullname: 大谷 博 – sequence: 5 fullname: 中園 清 – sequence: 6 fullname: 村澤 章 – sequence: 7 fullname: 石川 肇 – sequence: 8 fullname: 小林 大介 – sequence: 9 fullname: 佐藤 弘恵 – sequence: 10 fullname: 髙井 千夏 – sequence: 11 fullname: Hasegawa Eriko – sequence: 12 fullname: 黒澤 陽一 – sequence: 13 fullname: 坂井 俊介 – sequence: 14 fullname: 牧野 雄一 |
| Author_xml | – sequence: 1 fullname: Takai, Chinatsu organization: Division of Clinical Nephrology and Rheumatology Niigata University Graduate School of Medical and Dental Sciences – sequence: 1 fullname: Kodama, Satoru organization: Division of Endocrinology, Metabolism, and Rheumatology, Department of Internal Medicine, Asahikawa Medical University – sequence: 1 fullname: Murasawa, Akira organization: Department of Rheumatology, Niigata Rheumatic Center – sequence: 1 fullname: Makino, Yuichi organization: Center for Integrated Medical Education and Regional Symbiosis, Asahikawa Medical University – sequence: 1 fullname: Otani, Hiroshi organization: Department of Rheumatology, Niigata Rheumatic Center – sequence: 1 fullname: Sato, Hiroe organization: Division of Clinical Nephrology and Rheumatology Niigata University Graduate School of Medical and Dental Sciences – sequence: 1 fullname: Sakai, Shunsuke organization: Division of Clinical Nephrology and Rheumatology Niigata University Graduate School of Medical and Dental Sciences – sequence: 1 fullname: Nakazono, Kiyoshi organization: Department of Rheumatology, Niigata Rheumatic Center – sequence: 1 fullname: Abe, Asami organization: Department of Rheumatology, Niigata Rheumatic Center – sequence: 1 fullname: Ito, Satoshi organization: Department of Rheumatology, Niigata Rheumatic Center – sequence: 1 fullname: Hasegawa, Eriko organization: Division of Clinical Nephrology and Rheumatology Niigata University Graduate School of Medical and Dental Sciences – sequence: 1 fullname: Ishikawa, Hajime organization: Department of Rheumatology, Niigata Rheumatic Center – sequence: 1 fullname: Kobayashi, Daisuke organization: Division of Clinical Nephrology and Rheumatology Niigata University Graduate School of Medical and Dental Sciences – sequence: 1 fullname: Kurosawa, Yoichi organization: Division of Clinical Nephrology and Rheumatology Niigata University Graduate School of Medical and Dental Sciences |
| BackLink | https://cir.nii.ac.jp/crid/1390583015668366208$$DView record in CiNii |
| BookMark | eNpFkE1LxDAQhoOs4Ppx8g_k4LVr0qRpc_Agsn7AghfvZTaZ2EibliQi-0_8ubau4OUdmOedGeY9J6swBiTkmrMNl1rxWxNhI9SGc3lC1iVvdMEqXa3Immkui6ZW7IxcpeT3jEnGuG7KNfneOucNmAOFYGkCh_lAR0dhDxkMTpmacZggoqVfPncUMwSMv8AHOkH2GHI6stjh5wB59JZCzF302afFlTukEaGnX2PsLf1MPrzTKY4ThuTnc8mMEek8abqFDJi70V6SUwd9wqu_ekHeHrdvD8_F7vXp5eF-V3w0oilkVWJlrEKsealcXdVS7jVIKW1tnOXO6pILWTJrHK-Y0FZrziSAqZkRDsQFuTmuDd63xi_KhWZVIxivlGqEUiVrZtvd0faRMrxjO0U_QDy085_e9NjO0bdCteUic_7__Q5ii0H8AFejgwY |
| ContentType | Journal Article |
| Copyright | 2024 The Japanese Society for Clinical Rheumatology and Related Research |
| Copyright_xml | – notice: 2024 The Japanese Society for Clinical Rheumatology and Related Research |
| DBID | RYH |
| DOI | 10.14961/cra.36.114 |
| DatabaseName | CiNii Complete |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| DocumentTitleAlternate | 実臨床における高齢関節リウマチ患者へのアバタセプトの使用経験～プロペンシティスコアマッチング法によるエタネルセプトとの比較 |
| DocumentTitle_FL | 実臨床における高齢関節リウマチ患者へのアバタセプトの使用経験～プロペンシティスコアマッチング法によるエタネルセプトとの比較 |
| EISSN | 2189-0595 |
| EndPage | 130 |
| ExternalDocumentID | article_cra_36_2_36_114_article_char_en |
| GroupedDBID | ALMA_UNASSIGNED_HOLDINGS JSF KQ8 RJT RYH |
| ID | FETCH-LOGICAL-j838-452e5cd6ee7126f75744b9a444d7cfd1fd9213420dcf15039d99104aac70c3fa3 |
| ISSN | 0914-8760 |
| IngestDate | Thu Jun 26 21:10:36 EDT 2025 Wed Sep 03 06:30:19 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 2 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j838-452e5cd6ee7126f75744b9a444d7cfd1fd9213420dcf15039d99104aac70c3fa3 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/cra/36/2/36_114/_article/-char/en |
| PageCount | 17 |
| ParticipantIDs | nii_cinii_1390583015668366208 jstage_primary_article_cra_36_2_36_114_article_char_en |
| PublicationCentury | 2000 |
| PublicationDate | 2024 |
| PublicationDateYYYYMMDD | 2024-01-01 |
| PublicationDate_xml | – year: 2024 text: 2024 |
| PublicationDecade | 2020 |
| PublicationTitle | Clinical Rheumatology and Related Research |
| PublicationTitleAlternate | Clinical Rheumatology and Related Research |
| PublicationTitle_FL | Clinical Rheumatology and Related Research 臨床リウマチ |
| PublicationYear | 2024 |
| Publisher | The Japanese Society for Clinical Rheumatology and Related Research 一般社団法人 日本臨床リウマチ学会 |
| Publisher_xml | – name: The Japanese Society for Clinical Rheumatology and Related Research – name: 一般社団法人 日本臨床リウマチ学会 |
| References | 9） Turkcapar N, Demir O, Atli T, et al: Late onset rheumatoid arthritis: clinical and laboratory comparisons with younger onset patients. Arch Gerontol Geriatr, 42: 225-231, 2006. 10） Mavragani CP, Moutsopoulos HM: Rheumatoid arthritis in the elderly. Exp Gerontol, 34: 463-471, 1999. 8） Sugihara T, Harigai M: Targeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic Drugs. Drugs Aging, 33: 97-107, 2016. 14） Harigai M, Ishiguro N, Inokuma S, et al: Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. Mod Rheumatol, 26: 491-498, 2016. 33） Devine EB, Alfonso-Cristancho R, Sullivan SD: Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. Pharmacotherapy, 31: 39-51, 2011. 7） Boots AMH, Maier AB, Stinissen P, et al: The influence of ageing on the development and management of rheumatoid arthritis. Nat Rev Rheumatol, 9: 604-613, 2013. 1） Yamada H, Tanaka E, Nakajima A, et al: A large observational cohort study of rheumatoid arthritis, IORRA: Providing context for todayʼs treatment options. Mod Rheumatol, 30: 1-6, 2019. 11） Holroyd CR, Seth R, Bukhari M, et al: The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis: Rheumatology（Oxford）, 58: 3-42, 2019. 31） Tvete IF, Natvig B, Gåsemyr J, et al: Comparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression Analysis. PLoS One, 10: e0137258, 2015. 16） Fleischmann RM, Baumgartner SW, Tindall EA, et al: Response to etanercept（Enbrel）in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. J Rheumatol, 30: 691-696, 2003. 24） Lahaye C, Soubrier M, Mulliez A, et al: Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology’s ORA registry. Rheumatology（Oxford）, 55: 874-882, 2016. 25） Sekiguchi M, Fujii T, Matsui K, et al: Differences in predictive factors for sustained clinical remission with abatacept between younger and elderly patients with biologic-naive rheumatoid arthritis: results from the ABROAD Study. J Rheumatol, 43: 1974-1983, 2016. 6） Treharne GJ, Douglas KM, Iwaszko J, et al: Polypharmacy among people with rheumatoid arthritis: The role of age, disease duration and comorbidity. Musculoskeletal Care, 5: 175-190, 2007. 29） Stamm TA, Reichardt B, Zwerina J, et al: Use of biological disease modifying antirheumatic drugs in rheumatoid arthritis in Austria from 2008 to 2011: A retrospective analysis of 72% of the population. Wien Klin Wochenschr, 130: 230-237, 2018. 19） Kodama S, Ito S, Kobayashi D, et al: Efficacy and safety of etanercept in rheumatoid arthritis patients over 75 years of age. Clin Rheumatol Rel Res, 29: 238-250, 2017. 17） Lurati A, Marrazza M, Angela K, et al: Safety of etanercept in elderly subjects with rheumatoid arthritis. Biologics, 4: 1-4, 2010. 4） Kojima M, Nakayama T, Tsutani K, et al: Epidemiological characteristics of rheumatoid arthritis in Japan: Prevalence estimates using a nationwide population-based questionnaire survey. Mod Rheumatol, 30: 941-947, 2020. 2） Kato E, Sawada T, Tahara K, et al: The age at onset of rheumatoid arthritis is increasing in Japan: a nationwide database study. Int J Rheum Dis, 20: 839-845, 2017. 15） Bathon JM, Fleischmann RM, van der Heijde DM, et al: Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol, 33: 234-243, 2006. 30） Takabayashi K, Ando F, Suzuki T: Comparing the effectiveness of biological disease-modifying antirheumatic drugs using real-world data. Mod Rheumatol, 29: 87-97, 2019. 26） 綾部敬生，鵜飼康二，大関健司ら：肺障害を合併した70歳以上の関節リウマチ患者に対するアバタセプトの長期成績─当院でのアバタセプト（ABT）投与後3年経過例106例の検討から─．日関病誌，37: 77-85, 2018. 21） 平田純生，柴田啓智，宮村重幸ら：患者腎機能の正確な評価の理論と実践．日腎薬誌，5: 3-18, 2016. 5） Mori S, Yoshitama T, Hirakata N, et al: Prevalence of and factors associated with renal dysfunction in rheumatoid arthritis patients: a cross-sectional study in community hospitals. Clin Rheumatol, 36: 2673-2682, 2017. 23） Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplantation, 48: 452-458, 2013. 28） Ebina K, Hashimoto M, Yamamoto W, et al: Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis ‒The ANSWER cohort study‒. PLoS One, 14: e0216624, 2019. 39） Mori S, Yoshitama T, Hidaka T, et al: Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan. PLoS One, 12: e0179179, 2017. 3） Nakajima A, Sakai R, Inoue E, et al: Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan. Int J Rheum Dis, 23: 1676-1684, 2020. 38） Carrara G, Bortoluzzi A, Sakellariou G, et al: Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECord linkage On Rheumatic Disease study of the Italian Society for Rheumatology. Clin Exp Rheumatol, 37: 60-66, 2019. 12） アバタセプト使用成績調査（全例調査）適正使用情報vol.5 2021年11月 27） 木島靖文，荒井勝光，近藤直樹ら：関節リウマチ症例におけるアバタセプトの臨床成績．新潟整外研会誌，37: 39-44, 2021. 37） Yun H, Xie F, Delzell E, et al: Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in medicare. Arthritis Rheum, 68: 56-66，2016. 13） Harigai M, Ishiguro N, Inokuma S, et al: Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance. Mod Rheumatol, 29: 747-755, 2019. 22） Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron, 16: 31-41, 1976. 36） George MD, Baker JF, Winthrop K, et al: Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis: A Cohort Study. Ann Intern Med, 173: 870-878, 2020. 35） 大島幹弘：リウマチ患者における生物学的製剤投与時の併用薬への影響．医療薬学，39: 388-393, 2013. 20） Inoue E, Yamanaka H, Hara M, et al: Comparison of Disease Activity Score（DAS）28-erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann Rheum Dis, 66: 407-409, 2007. 32） Hirabara S, Takahashi N, Fukaya N, et al: Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies. Clin Rheumatol, 33: 1247-1254, 2014. 18） 児玉暁，伊藤聡，小林大介ら：75歳以上の高齢関節リウマチ患者におけるエタネルセプトの投与経験．中部リウマチ，45: 14-18，2015. 34） Kondo M, Yamada H: Drug survival rates of biological disease-modifying antirheumatic drugs and Janus kinase-inhibitor therapy in 801 rheumatoid arthritis patients: a 14 year-retrospective study from a rheumatology clinic in Japan. Mod Rheumatol, 29: 928-935, 2019. |
| References_xml | – reference: 31） Tvete IF, Natvig B, Gåsemyr J, et al: Comparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression Analysis. PLoS One, 10: e0137258, 2015. – reference: 39） Mori S, Yoshitama T, Hidaka T, et al: Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan. PLoS One, 12: e0179179, 2017. – reference: 27） 木島靖文，荒井勝光，近藤直樹ら：関節リウマチ症例におけるアバタセプトの臨床成績．新潟整外研会誌，37: 39-44, 2021. – reference: 8） Sugihara T, Harigai M: Targeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic Drugs. Drugs Aging, 33: 97-107, 2016. – reference: 3） Nakajima A, Sakai R, Inoue E, et al: Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan. Int J Rheum Dis, 23: 1676-1684, 2020. – reference: 20） Inoue E, Yamanaka H, Hara M, et al: Comparison of Disease Activity Score（DAS）28-erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann Rheum Dis, 66: 407-409, 2007. – reference: 6） Treharne GJ, Douglas KM, Iwaszko J, et al: Polypharmacy among people with rheumatoid arthritis: The role of age, disease duration and comorbidity. Musculoskeletal Care, 5: 175-190, 2007. – reference: 13） Harigai M, Ishiguro N, Inokuma S, et al: Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance. Mod Rheumatol, 29: 747-755, 2019. – reference: 36） George MD, Baker JF, Winthrop K, et al: Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis: A Cohort Study. Ann Intern Med, 173: 870-878, 2020. – reference: 1） Yamada H, Tanaka E, Nakajima A, et al: A large observational cohort study of rheumatoid arthritis, IORRA: Providing context for todayʼs treatment options. Mod Rheumatol, 30: 1-6, 2019. – reference: 14） Harigai M, Ishiguro N, Inokuma S, et al: Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. Mod Rheumatol, 26: 491-498, 2016. – reference: 12） アバタセプト使用成績調査（全例調査）適正使用情報vol.5 2021年11月． – reference: 37） Yun H, Xie F, Delzell E, et al: Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in medicare. Arthritis Rheum, 68: 56-66，2016. – reference: 16） Fleischmann RM, Baumgartner SW, Tindall EA, et al: Response to etanercept（Enbrel）in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. J Rheumatol, 30: 691-696, 2003. – reference: 29） Stamm TA, Reichardt B, Zwerina J, et al: Use of biological disease modifying antirheumatic drugs in rheumatoid arthritis in Austria from 2008 to 2011: A retrospective analysis of 72% of the population. Wien Klin Wochenschr, 130: 230-237, 2018. – reference: 33） Devine EB, Alfonso-Cristancho R, Sullivan SD: Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. Pharmacotherapy, 31: 39-51, 2011. – reference: 15） Bathon JM, Fleischmann RM, van der Heijde DM, et al: Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol, 33: 234-243, 2006. – reference: 18） 児玉暁，伊藤聡，小林大介ら：75歳以上の高齢関節リウマチ患者におけるエタネルセプトの投与経験．中部リウマチ，45: 14-18，2015. – reference: 7） Boots AMH, Maier AB, Stinissen P, et al: The influence of ageing on the development and management of rheumatoid arthritis. Nat Rev Rheumatol, 9: 604-613, 2013. – reference: 2） Kato E, Sawada T, Tahara K, et al: The age at onset of rheumatoid arthritis is increasing in Japan: a nationwide database study. Int J Rheum Dis, 20: 839-845, 2017. – reference: 28） Ebina K, Hashimoto M, Yamamoto W, et al: Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis ‒The ANSWER cohort study‒. PLoS One, 14: e0216624, 2019. – reference: 5） Mori S, Yoshitama T, Hirakata N, et al: Prevalence of and factors associated with renal dysfunction in rheumatoid arthritis patients: a cross-sectional study in community hospitals. Clin Rheumatol, 36: 2673-2682, 2017. – reference: 24） Lahaye C, Soubrier M, Mulliez A, et al: Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology’s ORA registry. Rheumatology（Oxford）, 55: 874-882, 2016. – reference: 38） Carrara G, Bortoluzzi A, Sakellariou G, et al: Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECord linkage On Rheumatic Disease study of the Italian Society for Rheumatology. Clin Exp Rheumatol, 37: 60-66, 2019. – reference: 9） Turkcapar N, Demir O, Atli T, et al: Late onset rheumatoid arthritis: clinical and laboratory comparisons with younger onset patients. Arch Gerontol Geriatr, 42: 225-231, 2006. – reference: 19） Kodama S, Ito S, Kobayashi D, et al: Efficacy and safety of etanercept in rheumatoid arthritis patients over 75 years of age. Clin Rheumatol Rel Res, 29: 238-250, 2017. – reference: 17） Lurati A, Marrazza M, Angela K, et al: Safety of etanercept in elderly subjects with rheumatoid arthritis. Biologics, 4: 1-4, 2010. – reference: 25） Sekiguchi M, Fujii T, Matsui K, et al: Differences in predictive factors for sustained clinical remission with abatacept between younger and elderly patients with biologic-naive rheumatoid arthritis: results from the ABROAD Study. J Rheumatol, 43: 1974-1983, 2016. – reference: 30） Takabayashi K, Ando F, Suzuki T: Comparing the effectiveness of biological disease-modifying antirheumatic drugs using real-world data. Mod Rheumatol, 29: 87-97, 2019. – reference: 21） 平田純生，柴田啓智，宮村重幸ら：患者腎機能の正確な評価の理論と実践．日腎薬誌，5: 3-18, 2016. – reference: 22） Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron, 16: 31-41, 1976. – reference: 10） Mavragani CP, Moutsopoulos HM: Rheumatoid arthritis in the elderly. Exp Gerontol, 34: 463-471, 1999. – reference: 23） Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplantation, 48: 452-458, 2013. – reference: 35） 大島幹弘：リウマチ患者における生物学的製剤投与時の併用薬への影響．医療薬学，39: 388-393, 2013. – reference: 11） Holroyd CR, Seth R, Bukhari M, et al: The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis: Rheumatology（Oxford）, 58: 3-42, 2019. – reference: 34） Kondo M, Yamada H: Drug survival rates of biological disease-modifying antirheumatic drugs and Janus kinase-inhibitor therapy in 801 rheumatoid arthritis patients: a 14 year-retrospective study from a rheumatology clinic in Japan. Mod Rheumatol, 29: 928-935, 2019. – reference: 32） Hirabara S, Takahashi N, Fukaya N, et al: Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies. Clin Rheumatol, 33: 1247-1254, 2014. – reference: 4） Kojima M, Nakayama T, Tsutani K, et al: Epidemiological characteristics of rheumatoid arthritis in Japan: Prevalence estimates using a nationwide population-based questionnaire survey. Mod Rheumatol, 30: 941-947, 2020. – reference: 26） 綾部敬生，鵜飼康二，大関健司ら：肺障害を合併した70歳以上の関節リウマチ患者に対するアバタセプトの長期成績─当院でのアバタセプト（ABT）投与後3年経過例106例の検討から─．日関病誌，37: 77-85, 2018. |
| SSID | ssib004001982 ssj0003304618 ssib029852172 ssib058494229 |
| Score | 2.339893 |
| Snippet | Objective: There are increasing opportunities to use biological disease-modifying antirheumatic drugs and Janus kinase inhibitors, even in elderly patients... |
| SourceID | nii jstage |
| SourceType | Publisher |
| StartPage | 114 |
| SubjectTerms | abatacept efficacy elderly rheumatoid arthritis safety |
| Title | Efficacy and safety of abatacept compared with etanercept in patients with rheumatoid arthritis in the real world using propensity score matching method |
| URI | https://www.jstage.jst.go.jp/article/cra/36/2/36_114/_article/-char/en https://cir.nii.ac.jp/crid/1390583015668366208 |
| Volume | 36 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Clinical Rheumatology and Related Research, 2024, Vol.36(2), pp.114-130 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LjtMwFLU6w4YNAgFigEFe4FWVoYkdx16GUVABAQKKNLvISRw1laZFabvhS_g_foR77bx4SDw2lus4SeN7Yh879x4T8rQCFi1VaAMu4yoQmuugKEroDMtCJmHIa-6Cwt68lctP4tVVfDWbfZt4LR0PxUX55bdxJf9jVSgDu2KU7D9YdrgoFEAe7AspWBjSv7JxhvoPuF-7W_02tfXuFaYwB4PuKj95mFsggt6PZT4qqnbhbe3aHoG87poKZY_WTuqo94FsUXzYSavOj3sfvY6bbjlvjj3KYM7hTO-T6TeknjJelimmEpYqlsXsecpUyjLOFGepz0QslV2JzrqMGnCAJ6mY6QXLEqYypvScZZLpdFLnJdDnj_DX9-tm_JhlAXjmeih4B4_ezJdNO9TqVjqicY3TRckBd8A9OX_wZr3so0c_dI00yFY5V0JbDf6L04XPUOAY4L8GWVcGPEcHQDTj6bjghVk6_EeTTj70Ya8dXwj9d6VfhiKhJY5FZWsuuERJ5hNyI0qSEP1OX79X00401KPAUKRVjJuG9b-BIGoRdRwW6QV3GvmOYfRP0sWd4h2fjfcDTrWBGQZKR5xsm2ZCm1a3ya1uvkNTD947ZLYxd8nXHrgUGpF64NJdTQfg0h64FMFJR-DSZkt74PpjI3DpAFysBcClCFzqgEsdcOkIXOqAS3vgUg_ce2T1IltdLoNui5Bgo2CkFnFk47KS1iZhJOskToQotBFCVElZV2FdaVQsjBZVWcPMh-sKpkMLYUyZLEpeG36fnG53W_uA0MqWqq6NKeCAWNS2KAwMVTXwV6NDHsszIn1r5p-9DEzevfY5tHjOZR5hAs0-lq9NC73UGTmH1s_LBlOYb4FFOeoXSMWljBbq4R-OPyI38WXwy36PyemhPdpzIMKH4okD0ncD9q4R |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+and+safety+of+abatacept+compared+with+etanercept+in+patients+with+rheumatoid+arthritis+in+the+real+world+using+propensity+score+matching+method&rft.jtitle=%E8%87%A8%E5%BA%8A%E3%83%AA%E3%82%A6%E3%83%9E%E3%83%81&rft.au=%E5%85%90%E7%8E%89+%E6%9A%81&rft.au=Ito+Satoshi&rft.au=Abe+Asami&rft.au=Otani+Hiroshi&rft.date=2024&rft.pub=The+Japanese+Society+for+Clinical+Rheumatology+and+Related+Research&rft.issn=0914-8760&rft.eissn=2189-0595&rft.volume=36&rft.issue=2&rft.spage=114&rft.epage=130&rft_id=info:doi/10.14961%2Fcra.36.114 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0914-8760&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0914-8760&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0914-8760&client=summon |